Abstract
Apoptosis or programmed cell death is a cellular mechanism used to regulate cell number and eliminate damaged or mutated cells. Many chemotherapeutic agents and ionizing radiation induce not only apoptotic signaling pathways, but also survival responses such as DNA damage responses and cell cycle arrest, which allow for DNA repair. These survival responses determine the toxicity as well as the efficacy of the cancer treatment. Two main DNA damage responses include the activation of the anti-apoptotic transcription factor NF-κB and the activation of cell cycle checkpoint kinases. Strategies of combining chemotherapeutics with (a) inhibitors of NF-κB or (b) inhibitors of checkpoint kinases, may therefore enhance the efficacy of current cancer therapies. This review will be focused on recent progress made in combining traditional chemotherapeutic drugs with small molecule inhibitors of NF-κB and the checkpoint kinases, Chk1 and Chk2.
Keywords: Chemotherapy, sensitization, potentiation, inhibition, cancer, NF-κB, IκB, proteasome, checkpoint kinases, checkpoint kinase I (Chk1)
Current Medicinal Chemistry
Title: Enhancement of Chemotherapeutic Efficacy by Small Molecule Inhibition of NF-κ B and Checkpoint Kinases
Volume: 14 Issue: 10
Author(s): Vasudha Sharma, Christopher D. Hupp and Jetze J. Tepe
Affiliation:
Keywords: Chemotherapy, sensitization, potentiation, inhibition, cancer, NF-κB, IκB, proteasome, checkpoint kinases, checkpoint kinase I (Chk1)
Abstract: Apoptosis or programmed cell death is a cellular mechanism used to regulate cell number and eliminate damaged or mutated cells. Many chemotherapeutic agents and ionizing radiation induce not only apoptotic signaling pathways, but also survival responses such as DNA damage responses and cell cycle arrest, which allow for DNA repair. These survival responses determine the toxicity as well as the efficacy of the cancer treatment. Two main DNA damage responses include the activation of the anti-apoptotic transcription factor NF-κB and the activation of cell cycle checkpoint kinases. Strategies of combining chemotherapeutics with (a) inhibitors of NF-κB or (b) inhibitors of checkpoint kinases, may therefore enhance the efficacy of current cancer therapies. This review will be focused on recent progress made in combining traditional chemotherapeutic drugs with small molecule inhibitors of NF-κB and the checkpoint kinases, Chk1 and Chk2.
Export Options
About this article
Cite this article as:
Sharma Vasudha, Hupp D. Christopher and Tepe J. Jetze, Enhancement of Chemotherapeutic Efficacy by Small Molecule Inhibition of NF-κ B and Checkpoint Kinases, Current Medicinal Chemistry 2007; 14 (10) . https://dx.doi.org/10.2174/092986707780362844
DOI https://dx.doi.org/10.2174/092986707780362844 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Potential of Statins for Individualized Colorectal Cancer Chemoprevention
Current Drug Targets Development of a Sensitive Cost-Effective Capture ELISA for Detection of Murine Monoclonal Antibodies - Correlation with SPR Biosensor Technology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Development of a Simple and Efficient Solution-Phase Parallel Synthesis of Flexible Non-Steroidal Estradiol Mimics
Combinatorial Chemistry & High Throughput Screening Editorial [Hot Topic: Pharmacogenomics: Achievements, Challenges and Prospects, for Patients, Pharmaceutical Industries and Healthcare Systems (Guest Editor: Despina Sanoudou)]
Current Pharmaceutical Design Non-Viral Gene Delivery to the Lungs
Current Gene Therapy Anticancer Activity and Topoisomerase II Inhibition of Naphthalimides with ω-Hydroxylalkylamine Side-Chains of Different Lengths
Medicinal Chemistry Endothelial Dysfunction in Diabetes: From Mechanisms to Therapeutic Targets
Current Medicinal Chemistry Recent Advances of Natural and Synthetic β-Carbolines as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Urease Inhibitory Activity of Some 5-Aminomethylene Barbituric/Thiobarbituric Acid Derivatives
Letters in Drug Design & Discovery Targeting Tuberculosis: A Glimpse of Promising Drug Targets
Mini-Reviews in Medicinal Chemistry Novel Antitumor Strategies Using Cytokine PEDF for Prostate Cancer Therapy
Current Angiogenesis (Discontinued) Regulation of Hepatic Transporters by Xenobiotic Receptors
Current Drug Metabolism Quality of Education and Memory Test Performance in Older Men: The New York University Paragraph Recall Test Normative Data
Current Alzheimer Research Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes
Current Pharmaceutical Design Cannabinoids and Psychosis
Current Pharmaceutical Design Perspectives in Tissue Microarrays
Combinatorial Chemistry & High Throughput Screening Development of COX-2 Selective Inhibitors - Therapeutic Perspectives
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Selenium-Enriched Yeast: As Selenium Source for Nutritional Purpose
Current Nutrition & Food Science Tumor Growth-Promoting Properties of Macrophage Migration Inhibitory Factor
Current Pharmaceutical Design O-6-methylguanine-DNA Methyltransferase Inhibits Gastric Carcinoma Cell Migration and Invasion by Downregulation of Matrix Metalloproteinase 2
Anti-Cancer Agents in Medicinal Chemistry